GRCE

Grace Therapeutics, Inc.

Healthcare · Biotechnology

$164.42 sample

+0.43 (+0.26%) 1D

Market cap

$956.6B

Price as of

2026-10-15

Latest filing

8-K · 2026-10-08

Alerts

8

Price$164.42 +11.11% 3M daily closessample

166.67145.86

2026-07-202026-08-112026-09-022026-09-232026-10-15

purchase / approvalsale / rejectionfiling / neutral

Latest events

Filings, trades, FDA; newest first

Oct 08SEC10-Q filed
Oct 01INSInsider sell: Chief Financial Officer
Sep 22SEC10-Q filed
Sep 16INSInsider sell: General Counsel
Sep 08INSInsider sell: Chief Executive Officer
Sep 01INSInsider sell: EVP, Operations
Aug 21INSInsider sell: EVP, Operations
Aug 18INSInsider sell: General Counsel

Sign up to see the real GRCE record →

Company facts

SEC EDGAR registration

Name: Grace Therapeutics, Inc.
Sector: Healthcare
Industry: Biotechnology
Smart-money score: +15sample, -100 to +100
Reporting currency: USD

Who is positioning in GRCE

sample

Insiders: 6 insider transactions over 90 days, net selling, $181.5M
Congress: 5 members traded over 90 days
Institutions · 13F: 36 funds hold $13.1B
Activists · 13D/G: No 13D/13G activist filings on record

How are the fundamentals trending?

sample, by period end

Revenue$45.4B +14.4% y/y

Q4 2024Q3 2026

Inventory$25.9B +10.8% y/y

Q4 2024Q3 2026

Accounts receivable$19.7B +15.4% y/y

Q4 2024Q3 2026

Total debt$55.0B +16.3% y/y

Q4 2024Q3 2026

Peers

sample

Sample peer A: $476.4B +15.3% 3M
Sample peer B: $798.7B +8.2% 3M
Sample peer C: $195.5B +9.0% 3M
Sample peer D: $302.0B +11.2% 3M
Sample peer E: $505.2B +4.2% 3M